© BusinessWire
28.11.2025
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRA...
Themefolio
Profiler
Peergroup
© PR Newswire
28.11.2025
SECT_B
LISTED
STO
Invitation to presentation of Sectra's six-month report 2025/2026
News Preview
LINKÖPING, Sweden, Nov. 28, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) invites investors, analysts, and the media to a presentation of the company's six-month report with President Torbjörn Kronander and CFO Jessica Holmquist.
Publication of the financial report: 8:15 a.m. (CET) on December...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.11.2025
GNFT
LISTED
EURONEXT
GENFIT Announces Appointment of new Chief Medical Officer
News Preview
GENFIT today announced the appointment of Dr. Pejvack Motlagh, the new Chief Medical Officer of GENFIT...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
27.11.2025
LEGN
LISTED
NASDAQ
Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade
News Preview
Recognizes the company’s continued investment and expansion of cell therapy manufacturing and R&D operations in Ghent, reinforcing Flanders’ position as a global biotech hub...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
27.11.2025
ORNBV
LISTED
HEL
71,498 Orion Corporation A shares converted into B shares
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 NOVEMBER 2025 at 9.00 EET ...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2025
CELC
LISTED
NASDAQ
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
News Preview
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) and is now available on the SABCS website. The 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2025
BAVA
LISTED
CPH
Bavarian Nordic to Host a Shareholder Information Meeting on December 11, 2025 in Copenhagen
News Preview
Bavarian Nordic invites shareholders to an information meeting with board and management on Dec 11, 09:00–10:30 CET in Copenhagen. Register by Dec 9....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2025
MURA
LISTED
NASDAQ
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
News Preview
WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”), XRA 5 Corp. (“Sub”) and Mural announced on August 20, 2025 (the “Transaction Agreement”), the...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2025
SKYE
LISTED
NASDAQ
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SKYE
News Preview
The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of SKYE during the c...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2025
CELC
LISTED
NASDAQ
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference
News Preview
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 8th Annual Evercore Healthcare Conference to be held in Miami, Florida on December 2-4, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
26.11.2025
SECT_B
LISTED
STO
Sectra launches its built-in reporting solution in the US--accelerates diagnostics for improved patient care
News Preview
LINKÖPING, Sweden, Nov. 26, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT-B) is introducing its built-in reporting solution for medical imaging, Sectra Reporting, to the US market. By unifying image review and reporting together in the diagnostic workflow, radiologists can work in a single applic...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2025
GLPG
LISTED
EURONEXT
Galapagos Receives Transparency Notifications from Bank of America
News Preview
Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
25.11.2025
ASND
LISTED
NASDAQ
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
News Preview
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Participation in December Investor Conferences
News Preview
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in mu...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY...
Themefolio
Profiler
Peergroup
© ActuNews
25.11.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – November 25, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on November 25, 2025, from Atlas Special Op...
Themefolio
Profiler
Peergroup
© ActuNews
25.11.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 25 november 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparantiekennisgeving...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2025
LIVN
LISTED
NASDAQ
LivaNova to Present at Piper Sandler Healthcare Conference in December
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City. The presentation will take place on Tues., Dec. 2, at 1:30 p.m. Eastern Stan...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2025
OGI
LISTED
NASDAQ
Organigram Announces Appointment of Chief Executive Officer
News Preview
Organigram Global Inc. (“Organigram” or the “Company”) (TSX: OGI) (NASDAQ: OGI), the parent company of Organigram Inc., a leading Canadian producer of cannabis, is pleased to announce that James Yamanaka, formerly Global Head of Strategy for British American Tobacco, has been appointed the Company’s new Chief Executive Officer (CEO). Mr. Yamanaka...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
AUTL
LISTED
NASDAQ
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
News Preview
the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending AUCATZYL®....
Themefolio
Profiler
Peergroup
© BusinessWire
24.11.2025
LIVN
LISTED
NASDAQ
LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) assigned VNS Therapy™, a LivaNova neuromodulation treatment for patients 4 years of age and older with Drug-Resistant Epilepsy (DRE) and focal seizures, to New Technology Ambulatory Payment Clas...
Themefolio
Profiler
Peergroup
© Newsfile
24.11.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Participate in Upcoming Investment Conferences
News Preview
San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences:Citi Global Healthcare Conference (Miami...
Themefolio
Profiler
Peergroup
© PR Newswire
24.11.2025
SECT_B
LISTED
STO
Sectra at RSNA 2025: Supporting subspecialty workflows and photon-counting CT at the workstation to reduce burnout risk and improve patient care
News Preview
LINKÖPING, Sweden, Nov. 24, 2025 /PRNewswire/ -- At this year's Radiological Society of North America's annual meeting (RSNA), international medical imaging IT and cybersecurity company Sectra (STO: SECT B) will present new developments designed to make radiology workflows even more efficient, not least by deep integration with AI. Sectra will sho...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.11.2025
FYB
LISTED
XETR
NTC wird Kommerzialisierungspartner für Formycons Eylea®-Biosimilar FYB203/Baiama® in Italien
News Preview
Pressemitteilung // 24. November 2025
NTC wird Kommerzialisierungspartner für Formycons Eylea®-Biosimilar FYB203/Baiama® in Italien
Planegg-Martinsried – Formycon AG (FWB: FYB, “Formycon”) und NTC s.r.l. (“NTC”) geben gemeinsam bekannt, dass die Klinge Biopharma GmbH (“Klinge”), Lizenznehmer und exklusiver Inhaber der weltweiten Vermarktungsr......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.11.2025
FYB
LISTED
XETR
NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy
News Preview
Press Release // November 24, 2025
NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) and NTC s.r.l. (“NTC”) jointly announce that Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global commercialization rights of Formycon......
Themefolio
Profiler
Peergroup
© Globe Newswire
24.11.2025
FAGR
LISTED
EURONEXT
Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business
News Preview
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 24 November 2025 – 7:00 AM CET...
Themefolio
Profiler
Peergroup
© BusinessWire
23.11.2025
BAYN
LISTED
XETR
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
News Preview
Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary efficacy and safety endpoints. Asundexian 50 mg once daily significantly reduced the risk of ischemic stroke compared to placebo, both in combination with ant...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.11.2025
BAYN
LISTED
XETR
Asundexian von Bayer erreicht primäre Wirksamkeits- und Sicherheitsendpunkte in zulassungsrelevanter Phase-III-Studie OCEANIC-STROKE zur Sekundärprävention von Schlaganfällen
News Preview
Leverkusen / Berlin, 23. November 2025 – Bayer hat heute positive Topline-Ergebnisse aus der globalen Phase-III-Studie OCEANIC-STROKE mit dem Prüfpräparat Asundexian, einem einmal täglich oral verabreichten FXIa-Hemmer, bekannt gegeben. Die Studie erreichte ihre primären Wirksamkeits- und Sicherheitsendpunkte. Asundexian, 50 mg einmal täglich, redu......
Themefolio
Profiler
Peergroup
© PR Newswire
21.11.2025
CTXR
LISTED
NASDAQ
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
News Preview
Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launchCRANFORD, N.J., Nov. 21, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius P...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.11.2025
ANAB
LISTED
NASDAQ
Anaptys Announces $100 Million Stock Repurchase Plan
News Preview
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company’s outs...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.11.2025
ANAB
LISTED
NASDAQ
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
News Preview
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. (“Tesaro”) has materially breached the parties’ Coll...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
News Preview
CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 15, 2025 to three new non-executive employees as equity induc...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
GMAB
LISTED
CPH
Grant of Restricted Stock Units and Warrants to Employees in Genmab
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© ActuNews
20.11.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – November 20, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on November 20, 2025, from Atlas Special Op...
Themefolio
Profiler
Peergroup
© ActuNews
20.11.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 20 november 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparantiekennisgeving...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
GNFT
LISTED
EURONEXT
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its third quarter 2025 financial results1 and provided a corporate update....
Themefolio
Profiler
Peergroup
© EQS Newswire
20.11.2025
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH
20.11.2025 / 17:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certai......
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
GNFT
LISTED
EURONEXT
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
News Preview
GENFIT announces the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Global Selec...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2025
BAYN
LISTED
XETR
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
News Preview
Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved HYRNUO® (sevabertinib), an oral, reversible, tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activat...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.11.2025
GXI
LISTED
XETR
Wechsel im Aufsichtsrat
News Preview
Gerresheimer AG: Wechsel im Aufsichtsrat
Klaus Röhrig folgt auf Dr. Dorothea Wenzel
Zusammensetzung des Aufsichtsrats spiegelt veränderte Eigentümerstruktur wider
Düsseldorf, 20. November 2025. Klaus Röhrig, Mitgründer und Co-Chief Investment Officer der Active Ownership Gruppe, wurde bis zur nächsten ordentlichen Hauptversammlung im Juni 2026......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.11.2025
GXI
LISTED
XETR
Change in the Supervisory Board
News Preview
Gerresheimer AG: Change in the Supervisory Board
Klaus Röhrig succeeds Dr. Dorothea Wenzel
Composition of the Supervisory Board reflects the changed shareholder structure
Duesseldorf, November 20, 2025. Klaus Röhrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresh......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.11.2025
FYB
LISTED
XETR
Ranibizumab-Biosimilar Epruvy® ab sofort in Deutschland verfügbar
News Preview
Pressemitteilung // 20. November 2025
Ranibizumab-Biosimilar Epruvy® ab sofort in Deutschland verfügbar
Sandoz vermarktet Epruvy®1 in Deutschland als Fertigspritze (PFS) und Durchstechflasche im Rahmen einer Lizenzvereinbarung mit der Bioeq AG
Die neue Fertigspritze kombiniert hohe Qualitätsstandards in der Biosimilar-Entwicklung mit einem b......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.11.2025
FYB
LISTED
XETR
Ranibizumab Biosimilar Epruvy® launched in Germany
News Preview
Press Release // November 20, 2025
Ranibizumab Biosimilar Epruvy® launched in Germany
Sandoz commercializes Epruvy®1 in innovative pre-filled syringe (PFS) and vial presentation in Germany under license from Bioeq AG
The PFS delivery system represents a key advancement combining biosimilar development excellence with customer-friendly design ......
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
IBAB
LISTED
EURONEXT
Third quarter 2025 update: IBA is highly confident to meet FY2025 guidance, and strengthens financing structure
News Preview
Louvain-la-Neuve, Belgium, 20 November 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, shares its business update for the third quarter of 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.11.2025
GMAB
LISTED
CPH
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2025
INDV
LISTED
NASDAQ
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference
News Preview
RICHMOND, Va., Nov. 19, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference:...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2025
ERF
LISTED
EURONEXT
Eurofins: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2025
BIOA B
LISTED
STO
New data on lecanemab to be presented at CTAD conference
News Preview
STOCKHOLM, Nov. 18, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease (CTAD) conference, being held in San Diego December 1-4. Presentations will include data on long-term treat...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2025
BIOA B
LISTED
STO
New data on lecanemab to be presented at CTAD conference
News Preview
STOCKHOLM, Nov. 18, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease (CTAD) conference, being held in San Diego December 1-4. Presentations will include data on long-term treat...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2025
INSP
LISTED
NYSE
INSP ALERT: Kirby McInerney LLP Reminds Inspire Medical Systems, Inc. Investors of Important Deadline in Class Action Lawsuit
News Preview
If you have suffered a loss on your Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE:INSP) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
Investors have...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2025
GMAB
LISTED
CPH
Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility
News Preview
Media Release...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2025
SKYE
LISTED
NASDAQ
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit With the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Inv...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2025
GMAB
LISTED
CPH
Capital Increase in Genmab as a Result of Employee Warrant Exercise
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2025
SKYE
LISTED
NASDAQ
Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”). Skye is a clinical stage biopharmaceutical company.
For more information, submit a fo...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2025
INSP
LISTED
NYSE
Deadline Alert: Inspire Medical Systems, Inc. (INSP) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming January 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, inclusive (th...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2025
GMAB
LISTED
CPH
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2025
TEM
LISTED
NASDAQ
Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:30 AM ET.
The live webcast...
Themefolio
Profiler
Peergroup
© EQS Newswire
18.11.2025
GXI
LISTED
XETR
Science Based Targets Initiative confirms CO2e Reduction Targets
News Preview
Gerresheimer: Science Based Targets Initiative confirms CO2e Reduction Targets
Targets align with the Paris Agreement to limit global warming to 1.5 °C
Reduction of Scope 1 and 2 emissions by 52% by 2030
Reduction of the intensity of selected Scope 3 emissions by 64% by 2034
Duesseldorf, November 18, 2025. Gerresheimer, an innovative system and......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.11.2025
GXI
LISTED
XETR
Science Based Targets Initiative bestätigt CO2e Reduktionsziele
News Preview
Gerresheimer: Science Based Targets Initiative bestätigt CO2e Reduktionsziele
Ziele stehen im Einklang mit dem Pariser Klimaabkommen zur Begrenzung der globalen Erwärmung auf 1,5 °C
Reduktion der Scope 1- und 2-Emissionen um 52 % bis 2030
Reduktion der Intensität ausgewählter Scope-3-Emissionen um
64 % bis 2034
Düsseldorf, 18. November Gerres......
Themefolio
Profiler
Peergroup
© Globe Newswire
17.11.2025
CELC
LISTED
NASDAQ
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
News Preview
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for gedatolisib in hormone receptor posit...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
